# Intratympanic Administration of N-acetylcysteine for Protection of Cisplatin-induced Ototoxicity

> **NCT04226456** · PHASE4 · TERMINATED · sponsor: **Centre Hospitalier Universitaire Saint Pierre** · enrollment: 19 (actual)

## Conditions studied

- Ototoxic Hearing Loss
- Ototoxic Hearing Loss, Bilateral
- Ototoxicity
- Tinnitus

## Interventions

- **DRUG:** N-acetyl cysteine

## Key facts

- **NCT ID:** NCT04226456
- **Lead sponsor:** Centre Hospitalier Universitaire Saint Pierre
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-07-10
- **Primary completion:** 2023-05-03
- **Final completion:** 2023-09-03
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** poor recruitment
- **Last updated:** 2023-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04226456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04226456, "Intratympanic Administration of N-acetylcysteine for Protection of Cisplatin-induced Ototoxicity". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04226456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*